Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia

  title={Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia},
  author={Evgeny L. Nasonov and A. M. Lila and Vadim I. Mazurov and B. S. Belov and Andrei E. Karateev and Tatiana V. Dubinina and O. A. Nikitinskaya and Alexander A. Baranov and Diana Abdulganieva and Sergei V. Moiseev and Alena I. Zagrebneva},
  journal={Rheumatology Science and Practice},
In mid-2021, the SARS-CoV-2 (Severe Acute Respiratory coronavirus 2) infection, which caused the coronavirus disease (COVID-19) pandemic, affected more than 157 million people in all regions of the world and led to more than 3.2 million deaths. It is assumed that elderly age, uncontrolled inflammation, anti-inflammatory therapy, comorbid pathology, genetic and other factors can potentially lead to an increase in “sensitivity” to viral and bacterial infections, including SARS-CoV-2. The new… 
16 Citations
Vaccination against SARS-CoV-2 in rheumatic diseases: Safety issues
The frequency of exacerbation of RD after vaccination against COVID-19 seems to be quite low (5–7%) and has no significant associations with a specific vaccine or anti-rheumatic therapy, and unambiguous interpretation is difficult.
B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19)
According to the recommendations of the Association of Rheumatologists of Russia, a more rigorous assessment of indications for induction and maintenance therapy of RTX therapy and harmonization of the timing of drug administration and vaccination is required.
Effect of COVID-19 coronavirus infection on the course of rheumatoid arthritis
The effect of coronavirus infection on the course of rheumatoid arthritis (RA), the severity of infection, the effect of current baseline therapy on infection outcomes, and the role of vaccination against COVID-19 were assessed.
Safety of COVID-19 vaccines in patients with immunoinflammatory rheumatic diseases (preliminary data)
Preliminary data suggest that vaccination against COVID-19 in patients with IRD appears to be quite safe, and further studies are needed to investigate the safety, immunogenicity, and clinical efficacy of CO VID-19 immunization in rheumatic patients.
Musculoskeletal manifectations of the new coronavirus infection: focus on arthralgia and myalgia
Use of non-steroid anti-inflammatory drugs and vitamin D during COVID-19 is a safe and effective method of pain management, including myalgia and arthralgia, but in some cases pain management is necessary.
Detection of SARS-Cov-2 N-protein in Mesenchymal Cells of Umbilical Warton's Jelly in Women with COVID-19
The results suggesting persistence of COVID-19 viral proteins in mesenchymal cells of the umbilical cord could be an important in establishing new pathogenic mechanisms for the fetal protection against viruses are suggested.
Anti-inflammatory drugs and immunogenicity of vaccines in patients with rheumatic diseases
The latest data on the effect of various anti-rheumatic drugs on the immunogenicity of vaccines against influenza, pneumococcal and herpes virus infections, viral hepatitis B, yellow fever and COVID-19 used in rheumatological patients are presented.
Vaccination in persons with systemic lupus erythematosus: the current state of the problem
It has been shown that the benefits of vaccination in patients with SLE significantly outweigh the risk of adverse events or exacerbations of the disease, and the problem of vaccination of such patients requires further study.
Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology
The current achievements, trends and recommendations regarding the use of JAK inhibitors in the treatment of IMIDs and also in the hyper-response phase of COVID-19 are reviewed.
Organ changes after SARS-CoV-2 infection in a patient with systemic sclerosis according to autopsy
The article presents a description of a clinical case with a fatal outcome due to SARS-CoV-2 coronavirus-induced bilateral viral pneumonia with areas of pneumofibrosis, complicated by acute


Coronavirus disease 2019 (COVID-19) and autoimmunity
  • E. Nasonov
  • Medicine, Biology
    Rheumatology Science and Practice
  • 2021
Potential use of glucocorticoids, biologics, JAK inhibitors, etc., blocking the effects of pro-inflammatory cytokines for treatment of COVID-19 is discussed.
2019 Coronavirus disease (COVID-19): contribution of rheumatology
The article provides the basic provisions of the International and National Association of Rheumatologists and the Association of GPs of Russia recommendations for management of patients with IMRD during the COVID-19 pandemic.
COVID-19 and rheumatology: A year later
It was shown that the incidence of COVID-19 in patients with rheumatic diseases does not significantly differ from that in general population, and is not aggravated by preceding use of the majority of antirheumatic drugs.
COVID-19 and autoimmune diseases
A review of the association between COVID-19 and autoimmune diseases, focusing on similarities in immune responses, cross-reactivity of SARS-CoV-2, the development of autoimmune diseases in CO VID-19 patients and the risk of COVID -19 infection in patients with preexisting autoimmune conditions.
Characteristics of SARS-CoV-2 and COVID-19
The basic virology of SARS-CoV-2 is described, including genomic characteristics and receptor use, highlighting its key difference from previously known coronaviruses.
COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology
The uncertainty regarding the efficacy and safety of vaccination in patients with autoimmune inflammatory rheumatic disease (AIIRD), who are immunocompromised due to underlying immune dysfunction and concomitant immunosuppressive treatment, warrants clear guidance.
Post-COVID-19 arthritis: a case report and literature review
A case of acute oligoarthritis occurring 13 days after a SARS-CoV2 severe pneumonia in a middle-aged Caucasian man is described and it is hypothesized that molecular mimicry might be the basic immunological mechanism responsible for the onset of COVID-19-related arthritis.